Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

REVENUES (Tables)

REVENUES (Tables)

6 Months Ended

Jun. 30, 2024

Revenue From Contract With Customer [Abstract]

Summary of revenues disaggregated by category

Revenues disaggregated by category were as follows (in thousands):


	Three months ended June 30,				Six months ended June 30,
	2024		2023		2024		2023
Endari®	$	5,351	$	10,477	$	7,695	$	16,992
Other		26		282	$	188		520
Revenues, net	$	5,377	$	10,759	$	7,883	$	17,512

Revenue Allowance and Accrual Activities

The following table summarizes the revenue allowance and accrual activities for the six months ended June 30, 2024 and June 30, 2023 (in thousands):


	Trade Discounts, Allowances and Chargebacks			Government Rebates and Other Incentives			Returns			Total
Balance as of December 31, 2023	$	1,212		$	5,658		$	863		$	7,733
Provision related to sales in the current year		730			1,759			82			2,571
Adjustments related to prior period sales		(79	)		34			—			(45	)
Credits and payments made		(746	)		(765	)		(884	)		(2,395	)
Balance as of June 30, 2024	$	1,117		$	6,686		$	61		$	7,864

Balance as of December 31, 2022	$	1,358		$	3,718		$	415		$	5,491
Provision related to sales in the current year		1,213			2,095			262			3,570
Adjustments related to prior period sales		(213	)		136			—			(77	)
Credits and payments made		(1,463	)		(1,536	)		(360	)		(3,359	)
Balance as of June 30, 2023	$	895		$	4,413		$	317		$	5,625

Summarizes revenues from each of our customers accounted for 10% or more of net revenues

The following table summarizes revenues attributable to each of our customers that accounted for 10% or more of our net revenues in any of the periods shown:


	Three months ended June 30,						Six months ended June 30,
	2024			2023			2024			2023
Customer A		38	%		15	%		40	%		17	%
Customer B		26	%		15	%		30	%		15	%
Customer C		21	%		11	%		15	%		13	%
Customer D		0	%		21	%		0	%		16	%